Eli Lilly and Company (LLY)
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro. Lilly claims Mochi Health, Fella Health, Willow Health and Henry Meds are deceiving consumers and turning them away from Lilly's medicines.
Lilly sues four compounders over copies of weight-loss drugs
Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines.
Is Eli Lilly Stock a Buy?
Type 2 diabetes and obesity have become an increasing global healthcare problem, reaching near crisis proportions in the United States. The arrival of GLP-1 agonists, drugs that mimic hormones to slow digestion and quell hunger, offers a potential solution and has created one of the pharmaceutical industry's most lucrative opportunities in recent history.
Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note
Eli Lilly (LLY) closed at $827.54 in the latest trading session, marking a +1.16% move from the prior day.
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
5 Reasons To Buy Eli Lilly
Eli Lilly's stock price rise of 9% YTD might not look like a lot on its own, but in the context of the recent market decline, it's still a standout performance. With no end in sight for market uncertainty, the stock can continue to make gains, especially as its recent trial results are positive. The company's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?
Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NVO -7.78%) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management.
Eli Lilly: A New Leader In Weight Loss Drugs Is Clearly Emerging
Eli Lilly's recent Phase III results for its oral weight loss pill have demonstrated remarkable results. LLY has emerged as the frontrunner to tap into the next stage of growth through Orforglipron, potentially surpassing Novo Nordisk. Lilly's domestic capacity could provide it an edge against Denmark-based NVO, although supply chain risks imputed to tariffs cannot be downplayed.
